CHMP adopts positive opinion for MS drug Plegridy™ in EU

[MSUK]

Biogen Idec received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the marketing authorisation of Plegridy™ (peginterferon beta-1a), a pegylated interferon administered subcutaneously for adults with relapsing-remitting multiple sclerosis (RRMS).

The CHMP’s positive opinion is now referred to the European Commission (EC), which grants marketing authorization for medicines in the EU........ Read More - http://www.ms-uk.org/PEGylatedinterferonbeta